Jazz Pharmaceuticals (JAZZ+0.9%) moves higher today after Cantor Fitzgerald starts coverage with a Buy rating and $86.00 price target. Cantor calls JAZZ an attractive growth story that's been held back by generic concerns over its key revenue driver, Xyrem, a drug for the treatment of narcolepsy, which represents 69% of revenue.